AstraZeneca PLC (LON:AZN) Receives GBX 7,542.80 Average Target Price from Brokerages

AstraZeneca PLC (LON:AZN) has been assigned a consensus rating of “Moderate Buy” from the seven brokerages that are covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is GBX 7,542.80 ($97.65).

Several analysts have recently issued reports on the company. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of AstraZeneca in a report on Wednesday, February 19th. Berenberg Bank reiterated a “buy” rating and set a GBX 140 ($1.81) price objective on shares of AstraZeneca in a research report on Monday, January 27th. Finally, Shore Capital restated a “buy” rating on shares of AstraZeneca in a report on Friday, March 7th.

AstraZeneca Price Performance

Shares of AstraZeneca stock opened at £113.52 ($146.97) on Friday. The firm has a market cap of £218.42 billion, a PE ratio of 31.12, a PEG ratio of 0.86 and a beta of 0.17. The stock has a 50 day moving average of £115.59 and a 200 day moving average of £112.95. The company has a current ratio of 0.93, a quick ratio of 0.59 and a debt-to-equity ratio of 73.83. AstraZeneca has a 12 month low of GBX 9,670 ($125.19) and a 12 month high of £133.88 ($173.33).

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.